Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Gonadorelin

GnRH, Luteinizing Hormone-Releasing Hormone, LHRH, Factrel

Quick Stats
Studies 192
Trials 100
Completed EARLY PHASE1 INTERVENTIONAL NCT00757185

Compromised Microcirculation in Women With Polycystic Ovary Syndrome

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The scientific aims of the study are to determine how peripheral microcirculatory responsiveness is altered in obese women with Polycystic Ovary Syndrome (PCOS) during local heating and to determine the mechanism for testosterone effects on peripheral microcirculatory responsiveness in women with PCOS.

Detailed Description

In these studies, we propose to use the skin as a relatively non-invasive model to examine cardiovascular and endothelial function in obese women with and without PCOS. Data have indicated an important role for testosterone in influencing the peripheral microcirculation. While testosterone can lead to vasodilation in the peripheral microcirculation in both men and in women without PCOS, testosterone appears to induce vasoconstriction in women with PCOS. The differential response between women with and without PCOS, and between men and women may be the result of differential ET-1 actions in the vessel, and regulated by the receptor subtype is involved in these actions.

Interventions

Name: ganirelix acetate
Type: DRUG
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
Name: methyl testosterone
Type: DRUG
Description: testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day

Primary Outcomes

Measure: Skin blood flow and cutaneous vascular conductance
TimeFrame: 6 non consecutive days
Description:

Trial Information

NCT ID

NCT00757185

Status

Completed

Study Type

INTERVENTIONAL

Phases

EARLY PHASE1

Sponsor

Yale University

Last Updated

December 15, 2025